Nothing Special   »   [go: up one dir, main page]

About: Eftilagimod alpha

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Eftilagimod alpha (INN; development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection. Efti has three intended clinical settings: Eftilagimod alpha is in Phase II clinical testing. Currently, the main indications for the drug are metastatic breast cancer, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC).

Property Value
dbo:abstract
  • Eftilagimod alpha (INN; development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection. Efti has three intended clinical settings: * as adjuvant to cancer vaccines (in a low, effective dose of ~250 µg) * as first-line 'chemo-immunotherapy,' that is, combined with standard chemotherapy (e.g. paclitaxel) * in combination immunotherapy with PD-1 treatments (e.g. pembrolizumab) Eftilagimod alpha is in Phase II clinical testing. Currently, the main indications for the drug are metastatic breast cancer, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). (en)
dbo:alternativeName
  • ImmuFact (en)
dbo:casNumber
  • 1800476-36-1
dbo:fdaUniiCode
  • SJ82PK3HWA
dbo:wikiPageID
  • 46557481 (xsd:integer)
dbo:wikiPageLength
  • 20424 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1092937308 (xsd:integer)
dbo:wikiPageWikiLink
dbp:casNumber
  • 1800476 (xsd:integer)
dbp:legalStatus
  • Investigational (en)
dbp:synonyms
  • Efti, IMP321 (en)
dbp:tradename
  • ImmuFact (en)
dbp:unii
  • SJ82PK3HWA (en)
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Eftilagimod alpha (INN; development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection. Efti has three intended clinical settings: Eftilagimod alpha is in Phase II clinical testing. Currently, the main indications for the drug are metastatic breast cancer, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). (en)
rdfs:label
  • Eftilagimod alpha (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License